Encapsulation of poorly soluble drugs in polymer-drug conjugates: Effect of dual-drug nanoformulations on cancer therapy

Pharmaceutical Research

Volumn 31, Issue 6, 2014, Pages 1605-1615

  Senanayake, Thulani H ^a   Lu, Yaman ^a   Bohling, Anna ^a   Raja, Srikumar ^b,c   Band, Hamid ^b,c   Vinogradov, Serguei V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

17 AAG; dual drug nanoformulations; floxuridine; oral delivery; paclitaxel

Indexed keywords

CHOLESTERYL POLYVINYL ALCOHOL; CHOLESTERYL POLYVINYL ALCOHOL FLOXURIDINE; FLOXURIDINE; HEAT SHOCK PROTEIN 70; NANOCONJUGATE; PACLITAXEL; POLYMER; TANESPIMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MEDICINAL CHEMISTRY; SOLUBILITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYMERS; SOLUBILITY;

EID: 84902175055     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1265-3     Document Type: Article

References (27)

1. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3(7):415-24.
2. Abratt RP, Sandler A, Crino L, Steward WP, Shepherd FA, Green MR, et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol. 1998;25(4 Suppl 9):35-43.
3. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res. 2001;7(4):1079-86.
4. Rowinsky EK, Donehower RC. Paclitaxel (taxol). The New England journal of medicine. 1995;332(15):1004-14.
5. Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, et al. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003;51(4):328-36.
6. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4(4):1013-9.
7. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs. 2002;7(2):277-88.
8. Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011;96(11):1619-26.
9. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 2005;106(1):318-27.
10. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 2009;61(13):1203-13.
11. Senanayake TH, Warren G, Vinogradov SV. Novel anticancer polymeric conjugates of activated nucleoside analogues. Bioconjug Chem. 2011;22(10):1983-93.
12. Senanayake TH, Warren G, Wei X, Vinogradov SV. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Control Release. 2013;167(2):200-9.
13. Yonehara M, Minami Y, Kawata Y, Nagai J, Yahara I. Heat-induced chaperone activity of HSP90. J Biol Chem. 1996;271(5):2641-5.
14. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A. 1996;93(25):14536-41.
15. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, et al. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther. 2008;7(10):1630-40.
16. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast cancer research: BCR. 2000;2(5):331-4.
17. Hiraga T, Hata K, Ikeda F, Kitagaki J, Fujimoto-Ouchi K, Tanaka Y, et al. Preferential inhibition of bone metastases by 5′-deoxy-5-fluorouridine and capecitabine in the 4 T1/luc mouse breast cancer model. Oncol Rep. 2005;14(3):695-9.
18. Xiong MP, Yanez JA, Kwon GS, Davies NM, Forrest ML. A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats. J Pharm Sci. 2009;98(4):1577-86.
19. Hasenstein JR, Shin HC, Kasmerchak K, Buehler D, Kwon GS, Kozak KR. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther. 2012;11(10):2233-42.
20. Chen H, Kim S, He W, Wang H, Low PS, Park K, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir. 2008;24(10):5213-7.
21. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436(7050):568-72.
22. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T, di Tomaso E, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A. 2001;98(8):4628-33.
23. Wei X, Senanayake TH, Warren G, Vinogradov SV. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjug Chem. 2013;24(4):658-68.
24. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
25. Yamaoka T, Tabata Y, Ikada Y. Comparison of body distribution of poly(vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol. 1995;47(6):479-86.
26. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997;15(2):744-9.
27. Vinogradov SV, Kohli E, Zeman AD. Cross-linked polymeric Nanogel formulations of 5′-triphosphates of nucleoside analogs: role of the cellular membrane in drug release. Mol Pharm. 2005;2:449-61.